Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Approval Of Vabomere Could Help Alleviate TMC's Financial Troubles

Executive Summary

The antibiotic Vabomere demonstrated statistical superiority over Zosyn, and could be a more attractive option than existing treatments for complicated urinary tract infections.


Related Content

Finance Watch: Investment In Novel Antibacterials Gets A New Boost With Qpex Launch
Products For Flu, Lung Cancer, HIV And TTP Enter Final Stages Of Assessment In EU
Melinta: A Pure-Play Antibiotics Specialist Rises
Keeping Track: US FDA's Late Summer Approval Extravaganza Stars Three Novel Agents, Features Return Of Mylotarg
Phase III Data Give Medicines Company's Carbavance A Chance To Best Antibiotic Competitors
The Medicines Co Sells CV Products To Fund Pipeline


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts